Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 11,037 $ 17,116
Prepaid expenses and other current assets 606 827
Total Current Assets 11,643 17,943
Property and equipment, net 801 872
Deposits and other assets 23 23
Total Assets 12,467 18,838
Current Liabilities:    
Accounts payable 1,493 2,020
Accrued expenses 1,058 1,526
Warrant liabilities 1,428 4,083
Accrued employee benefits 1,016 2,074
Deferred rent 92 90
Total Current Liabilities 5,087 9,793
Long term deferred rent 377 402
Total Liabilities 5,464 10,195
Stockholders' Deficit:    
Common stock, $0.001 par value; 350,000,000 shares authorized, 128,648,365 issued and 128,566,886 outstanding 129 129
Additional paid-in capital 193,230 192,545
Accumulated deficit (196,545) (194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (3,186) (1,496)
Non-controlling interest (1,923) (1,914)
Total Stockholders' Deficit: (5,109) (3,410)
Total Liabilities and Stockholders' Deficit 12,467 18,838
Series A Preferred Stock [Member]    
Current Liabilities:    
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized,120,000 issued and outstanding $ 12,112 $ 12,053